Pruzanski et al., 1970 - Google Patents
The significance of lysozyme (muramidase) in rheumatoid arthritis. I. Levels in serum and synovial fluidPruzanski et al., 1970
- Document ID
- 2966453154731368995
- Author
- Pruzanski W
- Saito S
- Ogryzlo M
- Publication year
- Publication venue
- Arthritis & rheumatism: official Journal of the American College of rheumatology
External Links
Snippet
Lysozyme (muramidase)* activity was estimated in 120 serum and 67 synovial fluid samples from patients with rheumatoid arthritis. These data were compared with the activity in samples from healthy controls and from patients with other forms of arthritis. In 35% of the …
- 108010014251 Muramidase 0 title abstract description 136
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pruzanski et al. | The significance of lysozyme (muramidase) in rheumatoid arthritis. I. Levels in serum and synovial fluid | |
AU560087B2 (en) | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) | |
US4603106A (en) | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) | |
West et al. | Fibrotic healing of adult and late gestation fetal wounds correlates with increased hyaluronidase activity and removal of hyaluronan | |
US4822776A (en) | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) | |
Meyer | Mucoids and glycoproteins | |
Gallin et al. | Efficacy of ascorbic acid in Chediak-Higashi syndrome (CHS): Studies in humans and mice | |
LaMont et al. | Arachidonic acid stimulates mucin secretion in prairie dog gallbladder | |
Michelacci et al. | Urinary excretion of glycosaminoglycans in normal and stone forming subjects | |
Fenton et al. | Effect of glucosamine on interleukin‐1‐conditioned articular cartilage | |
Bhunchet et al. | Contribution of immune response to the hepatic fibrosis induced by porcine serum | |
US6419927B1 (en) | Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages | |
Lai et al. | Increased production of hyaluronan by peritoneal cells and its significance in patients on CAPD | |
TW201102653A (en) | Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention | |
Pipkorn et al. | Nasal mucosal mast cells and histamine in hay fever: effect of topical glucocorticoid treatment | |
Soto et al. | Increased concentration of the complement split product C5a in acute pyelonephritis during pregnancy | |
HOW et al. | T LYMPHOCYTE SENSITIZATION AND SUPPRESSOR T LYMPHOCYTE DEFECT IN PATIENTS LONG AFTER TREATMENT FOR GRAVES’DISEASE | |
US20120003178A1 (en) | Evaluating the therapeutic potential of a glucan | |
Feiner et al. | Bacterial lysis by lysozyme | |
Thompson et al. | Familial defect of polymorph neutrophil phagocytosis associated with absence of a surface glycoprotein antigen (OKMI) | |
RU2759469C1 (en) | Method for monitoring the effectiveness of antibiotic therapy in the treatment of acute pyelonephritis in infants | |
Ziff et al. | Aminotripeptidase content of synovial fluid in arthritic diseases | |
Burnard et al. | Beta‐endorphin levels in newborn cerebrospinal fluid | |
Bories et al. | Up-regulation of nitric oxide production by interferon-γ in cultured peritoneal macrophages from patients with cirrhosis | |
Pruzanski et al. | Lysozyme in rheumatic diseases |